[A clinico-immunological analysis of the efficacy of prospidin and azathioprine in systemic lupus erythematosus (the results of a 12-month observation)].
Prospidin and azathioprine were given to 28 and 12 SLE patients, respectively, in a controlled trial which implied subsequent clinical and immunological surveillance for 12 months. The data obtained in the trial provided evidence for true antilupus activity of prospidin in a total dose 3.0-9.8 g. Prospidin brought about improvement with a complete or partial remission of the lupus nephritis in 71%, serious side effects in 21%, lethality in 17.8%, secondary resistance in 10% of the patients treated. The clinical and immunocorrective effects conformed. Compared to azathioprine, prospidin can produce more pronounced and rapid effect, induced more marked immunodepression. It is better tolerated, has no cytopenia effect. The drugs mechanisms of action and criteria of the treatment efficacy are discussed. It is hold valid to use prospidin in long-term maintenance of SLE patients.
E V
EV
Benenson
E M
EM
Mirrakhimova
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D008297:Male; D011447:Prospidium / Q000627:therapeutic use*; D012074:Remission Induction; D013997:Time Factors
D011447:Prospidium; D001379:Azathioprine
Kliniko-immunologicheskiĭ analiz éffektivnosti prospidina i azatioprina pri sistemnoĭ krasnoĭ volchake (rezul'taty 12-mesiachnogo nabliudeniia).